Skip to main content
. 2012 Nov 9;26(6):441–446. doi: 10.1002/jcla.21544

Table 3.

Stratification Analysis of Associations between rs11614913 Genotypes and Severe Overall Toxicity by Selected Variables

Selected variables rs11614913 Group 1a Group 2b P OR (95% CI)c
Chemotherapy regimens
Platinum‐navelbine CT+TT 87 55 1.00 (reference)
CC 24 27 0.07 1.81(0.94–3.48)
Platinum‐gemcitabine CT+TT 35 10 1.00 (reference)
CC 11 14 0.006d 4.46 (1.55–12.82)
Platinum‐paclitaxel CT+TT 43 13 1.00 (reference)
CC 21 4 0.54 0.68 (0.20–2.36)
Platinum‐based drug
Cisplatin CT+TT 113 68 1.00 (reference)
CC 40 48 0.008d 2.04 (1.20–3.48)
Carboplatin CT+TT 61 20 1.00 (reference)
CC 23 6 0.74 0.84 (0.30–2.37)
Gender
Male CT+TT 124 60 1.00 (reference)
CC 47 41 0.02d 1.92 (1.13–3.25)
Female CT+TT 50 28 1.00 (reference)
CC 16 13 0.42 1.46 (0.60–3.57)
Age
≤57 CT+TT 90 36 1.00 (reference)
CC 36 31 0.01d 2.23 (1.91–4.16)
>57 CT+TT 84 52 1.00 (reference)
CC 27 23 0.36 1.39 (0.71–2.69)
TNM stage
CT+TT 75 29 1.00 (reference)
CC 28 19 0.09 1.88 (0.90–3.94)
CT+TT 100 59 1.00 (reference)
CC 35 35 0.08 1.68 (0.94–2.98)
Histological types
Adenocarcinoma CT+TT 104 53 1.00 (reference)
CC 44 34 0.15 1.54 (0.87–2.70)
Squamous cell CT+TT 33 18 1.00 (reference)
CC 10 10 0.23 1.93 (0.66–5.63)
a

Group 1 means any grade 1 or 2 overall toxicity.

b

Group 2 means any grade 3 or 4 overall toxicity.

c

Data were calculated by unconditional logistic regression, adjusting covariates were performance status and type of treatment regimen.

d

Data of statistical significance.

OR, odds ratios; CI, confidence intervals; TNM, tumor/node/metastasis.